#NewProduct

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug "Zazvey® Capsules 30mg" in Japan and has launched it in the market as a novel mechanism of action treatment with rapid onset.

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug 'Zavege® Capsules 30mg' in Japan and has started market launch as a novel mechanism of action treatment with rapid efficacy.

Astellas Pharma announced that the combination therapy of PADCEV (Enfortumab Vedotin) and Pembrolizumab improved event-free survival and overall survival in cisplatin-eligible muscle-invasive bladder cancer in the Phase III EV-304 trial.

Zasositinib (TAK-279) achieved primary endpoints in a Phase 3 clinical trial targeting patients with moderate to severe plaque psoriasis, with over half achieving PASI90 and approximately 30% achieving PASI100 at week 16.

Takeda Pharmaceutical Company Limited, in collaboration with Protagonist Therapeutics, announced 52-week data from the Phase 3 VERIFY trial of rusfertide in patients with polycythemia vera, demonstrating sustained hematocrit control and safety.